Federal health officials have declined to approve the psychedelic drug MDMA as a therapy for PTSD. Drugmaker Lykos ...

The US Food and Drug Administration's (FDA) decision not to approve midomafetamine-assisted therapy (MDMA-AT) for ...

Lykos Therapeutics filed an application for FDA approval of its version of MDMA-assisted therapy for PTSD in February 2024.

In a previous blog on the use of psychedelics to treat mental health disorders, we reported that the US Food and Drug Administration (FDA) ...

The FDA rejected MDMA therapy as a treatment for PTSD, with the advisory committee saying there is not enough evidence it was safe or effective. A setback to the use of psychedelics for the treatment ...

Critics addressed the elephant in the room during the FDA’s first public meeting on trauma since its decision to delay ...

A Food and Drug Administration (FDA) advisory panel overwhelmingly rejected MDMA-assisted therapy for treating post-traumatic ...

Delve into the psychedelic-assisted therapy market and investors' sentiment after the FDA's decision about Lykos' MDMA ...

Amy Emerson is stepping down on the heels of the FDA last month rejecting Lykos Therapeutics’ MDMA-based therapy for ...

The FDA was following the recommendation of an advisory panel that had expressed several concerns about two Phase 3 studies ...

The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...

MAPS has awarded a $200,000 grant to Emory University researchers for a pilot study that could redefine treatment for PTSD.